Ensign Peak Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Ensign Peak Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,500	Closed	-$54K	–	2214
2022 Q1	$54K	Hold	4,500	–	–	﹤0.01%	2119
2021 Q4	$147K	Sell	4,500 -5,500	-55%	-$223K	﹤0.01%	1990
2021 Q3	$447K	Hold	10,000	–	–	﹤0.01%	1645
2021 Q2	$545K	Hold	10,000	–	–	﹤0.01%	1582
2021 Q1	$748K	Buy	+10,000	New	+$1.04M	﹤0.01%	1511
2020 Q4	–	Sell	-2,598	Closed	-$230K	–	1886
2020 Q3	$230K	Buy	+2,598	New	+$295K	﹤0.01%	1655

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors's SYRS Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 4,500 shares — an estimated $54K sold.

Ensign Peak Advisors first reported a position in SYRS in Q3 2020 and held it in 6 quarters. The position peaked at $748K in Q1 2021. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

Ensign Peak Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Ensign Peak Advisors sold 4,500 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $54K.
Ensign Peak Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Ensign Peak Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $748K in Q1 2021.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.